Literature DB >> 7092541

Causes and evaluation of tumor-induced hypoglycemia.

S C Immerman, S F Sener, J D Khandekar.   

Abstract

We treated four patients who had hypoglycemia and nonpancreatic tumors. Two had pleural mesothelioma, one had primary fibrosarcoma of the liver, and one had pheochromocytoma metastatic to the liver. We propose four mechanisms for this syndrome: (1) insulin or insulin-like activity produced by the tumor, (2) decreased gluconeogenesis, (3) disruption of glucagon metabolism, and (4) increased utilization of glucose by the tumor. The local effects of the tumor in hepatic parenchyma may also play an important role. The important diagnostic tests are an insulin-glucose ratio, to rule out insulinoma, and fasting glucose levels. An assay of nonsuppressible insulin-like activity can be performed and is of investigative interest, but does not aid in individual patient therapy. Treatment consists of control of the tumor.

Entities:  

Mesh:

Year:  1982        PMID: 7092541     DOI: 10.1001/archsurg.1982.01380310025006

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  A case report of primary fibrosarcoma of the liver.

Authors:  Y Ito; Y Uesaka; S Takeshita; H Fujino; Y Uta; H Yasuda; M Oshima; T Kawabe; K Tagawa; T Unuma
Journal:  Gastroenterol Jpn       Date:  1990-12

2.  Cardiogenic shock triggered by phaeochromocytoma crisis after an oral glucose tolerance test: a case report.

Authors:  Bahira Shahim; Ulrika Ljung Faxén; Rebecka Stern; Anna Freyschuss
Journal:  Eur Heart J Case Rep       Date:  2019-10-11

3.  A case report of reactive hypoglycemia in a patient with pheochromocytoma and it's review of literature.

Authors:  Rajesh Patnaik Thonangi; Minaxi Bhardwaj; Bindu Kulshreshtha
Journal:  Indian J Endocrinol Metab       Date:  2014-03

4.  Ectopic insulin secreting neuroendocrine tumor of kidney with recurrent hypoglycemia: a diagnostic dilemma.

Authors:  S Ramkumar; Atul Dhingra; Vp Jyotsna; Mohd Ashraf Ganie; Chandan J Das; Amlesh Seth; Mehar C Sharma; Chandra Sekhar Bal
Journal:  BMC Endocr Disord       Date:  2014-04-17       Impact factor: 2.763

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.